| Literature DB >> 26786060 |
T Plug1, J C M Meijers1,2.
Abstract
Thrombin-activatable fibrinolysis inhibitor (TAFI) is an important regulator in the balance of coagulation and fibrinolysis. TAFI is a metallocarboxypeptidase that circulates in plasma as zymogen. Activated TAFI (TAFIa) cleaves C-terminal lysine or arginine residues from peptide substrates. The removal of C-terminal lysine residues from partially degraded fibrin leads to reduced plasmin formation and thus attenuation of fibrinolysis. TAFI also plays a role in inflammatory processes via the removal of C-terminal arginine or lysine residues from bradykinin, thrombin-cleaved osteopontin, C3a, C5a and chemerin. TAFI has been studied extensively over the past three decades and recent publications provide a wealth of information, including crystal structures, mutants and structural data obtained with antibodies and peptides. In this review, we combined and compared available data on structure/function relationships of TAFI.Entities:
Keywords: carboxypeptidase B2; carboxypeptidase R; carboxypeptidase U; fibrinolysis; thrombin-activatable fibrinolysis inhibitor (TAFI)
Mesh:
Substances:
Year: 2016 PMID: 26786060 DOI: 10.1111/jth.13261
Source DB: PubMed Journal: J Thromb Haemost ISSN: 1538-7836 Impact factor: 5.824